Committee on Energy and Commerce, Democrats Home Page
Who We Are Schedule What's New
View Printable Version
Home Page > Hearing - 110th Congress

HEARING


Programs Affecting Safety and Innovation in Pediatric Therapies

Subcommittee on Health
Tuesday, May 22, 2007, 10:00 a.m.
2322 Rayburn House Office Building


Hearing Webcast

An audio Webcast was not produced for this hearing due to technical difficulties. We apologize for the inconvenience.


Witness List & Prepared Testimony (pdf files)
Panel I
RADM Sandra L. Kweder, M.D.
Deputy Director
Office of New Drugs
Center for Drug Evaluation and Research (CDER)
U.S. Food and Drug Administration
10903 New Hampshire Ave.,
Room 5606
Silver Spring, MD 20993
Donald Mattison, M.D.
Chief
Obstetric and Pediatric Pharmacology Branch
National Institute of Child Health
and Human Development
National Institutes of Health
6100 Executive Boulevard, Room 4A01 Rockville, MD 20852
Accompanied by:
Joanne Less, Ph.D.
Acting Director
Office of Combination Products
U.S. Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857
 
Panel II
Ms. Lori Reilly
Vice President for Policy & Research
Pharmaceutical Research and Manufacturers
of America (PhRMA)
950 F Street, NW
Washington, DC 20005
Marcia Crosse, Ph.D.
Director
Health Care Issues
U.S. Government Accountability Office
441 G Street, NW, Room 5A14
Washington, DC 20548
Richard L. Gorman, M.D., F.A.A.P.
Chair
AAP Section on Clinical Pharmacology
and Therapeutics
American Academy of Pediatrics
601 13th Street, NW, Suite 400
Washington, DC 20005
Peter Lurie, M.D., M.P.H.
Deputy Director
Public Citizen’s Health Research Group
1600 20th Street, NW
Washington, DC 20009
Mr. Donald P. Lombardi
President and CEO
Institute for Pediatric Innovation
222 Berkeley Street, Suite 1650
Boston, MA 02116
Mr. Ed Rozynski
Vice President
Global Government Affairs
Stryker Corporation
2120 L Street, NW, Suite 245
Washington, DC 20037

Ms. Susan Belfiore
Princeton, NJ



Hearing Transcript

Not available at this time. The printed hearing should be available within 90-120 days of the conclusion of the hearing. When available, the text of the printed hearing may be viewed at the U.S. Government Printing Office Web site.